Daily MedNews
Printable Version   Email to a friend

Many Miss Out on Stroke Treatment

THURSDAY, Aug. 7 -- Most people who have strokes don't act quickly enough to get the clot-dissolving treatment that can limit brain damage, a new study finds.

"One of the problems is that a lot of people don't realize that they are having a stroke," said Kathryn M. Rose, a research associate professor of epidemiology at the University of North Carolina, and author of a report in the Aug. 8 online issue of Stroke. "There still needs to be a lot of education in the community for people to recognize these symptoms, and when you recognize them, call 911."

Hospital personnel can share some of the blame for tardy treatment, Rose added. "There is also delay time among people who get to the hospital quickly, so there is room for the medical community to act," she said.

Rose and her colleagues studied data on 15,117 people treated for strokes at 46 hospitals in North Carolina between 2005 and 2008. Treatment for an ischemic stroke, in which a clot blocks a blood vessel in the brain, is injection of clot-dissolving tissue plasminogen activator (tPA), but that is effective only in the first three hours after a stroke occurs.

In practice, that means arriving at a treatment center within two hours, Rose said, because, "once you get there, you need to be diagnosed. There's a very narrow window in which you can get treatment."

Only 23 percent of the people in the study arrived at hospitals within two hours of the onset of symptoms. The recommendation is that someone suspected of having a stroke should have a computerized tomography scan within 35 minutes to confirm the diagnosis. Of the 3,549 people who arrived within two hours of symptoms, only 23.6 percent had a CT scan in the recommended times.

"We found that women were less likely to get timely treatment," Rose said. "Also, treatment was faster in hospitals that were certified stroke centers, which have a formal plan for diagnosis and treatment."

Another important influence was the way people got to a hospital. "They were treated more quickly when they arrived by ambulance," Rose said. "It is better to call the EMS than to take yourself to the hospital."

People brought in by ambulance by the emergency medical service were twice as likely to get a timely CT scan, the study found. And while gender made a difference, race, health insurance status, time of day or weekend arrival did not.

"The whole thing is recognizing a stroke on both ends, the person who is having it, getting to the hospital in timely fashion, and also when they arrive at the hospital," said Dr. Claudette Brooks, an assistant professor of neurology at West Virginia University, and a spokeswoman for the American Stroke Association.

Brooks said she instructs people who believe they are having a stroke to get to the emergency room immediately, preferably by calling 911. If they do insist on driving to the hospital, they should call ahead, "so that when they walk in, they are not given a number by someone and put in a corner for several hours."

She advises against driving because, "if something happens, and it is a very severe stroke, and someone suddenly stops breathing, what are you going to do, stop the car and give CPR?"

While diagnosis and treatment might be quicker at a hospital with a stroke center, "the important thing is to get to any hospital right away," Brooks said.

The American Stroke Association teaches the public to watch for these warning signs:

  • Sudden numbness or weakness of the face, arm or leg, especially on one side of the body.
  • Sudden confusion, trouble speaking or understanding.
  • Sudden trouble seeing in one or both eyes.
  • Sudden trouble walking, dizziness, loss of balance or coordination.
  • Sudden, severe headache with no know cause.

More information

For more on stroke, go to American Heart Association.


Latest Daily MedNews...

Daily MedNews Archive

2008: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep
2007: Jul | Aug | Sep | Oct | Nov | Dec

More News Resources


MedNotes
Latest FDA Drug Alerts
September 4, 2008
Audience: Rheumatological, gastroenterological and infectious disease healthcare professionals[Posted 09/04/2008] FDA notified...
September 1, 2008
Audience: Emergency healthcare professionals, military emergency/disaster/field hospital/aviation personnel [Posted 08/28/2008]...
August 25, 2008
Audience: Neurologists, other healthcare professionals, patients[Posted 08/25/2008] FDA informed healthcare professionals of two...
August 21, 2008
Audience: Endocrinologists, cardiologists, other healthcare professionals, patients[Posted 08/21/2008] FDA informed healthcare...
More...
Latest Drug Information Updates

Xenazine
Xenazine (tetrabenazine) is a selective and reversible centrally-acting dopamine depleting drug indicated for the treatment of chorea associated with Huntington's disease.

Cleviprex
Cleviprex is an intravenous, ultrashort-acting calcium channel blocker under development for the treatment of severely elevated blood pressure in the hospital setting when oral therapy is not feasible or desirable.

Stavzor
Stavzor is delayed-release valproic acid formulated in the EnteriCare enteric soft gelatin capsule delivery system designed to minimize GI adverse events. Stavzor is indicated for the treatment of manic episodes associated with bipolar disorder, adjunctive therapy in multiple seizure types (including epilepsy), and prophylaxis of migraine headaches.

Navstel
Navstel is a balanced salt ophthalmic solution for use as an intraocular irrigation during surgical procedures involving perfusion of the eye.

Eovist
Eovist (gadoxetate disodium) is a gadolinium-based contrast agent for intravenous use in T1-weighted magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in adults with known or suspected focal liver disease.

Evolence
Evolence is a collagen-based structural dermal filler for the correction of moderate to deep facial wrinkles and folds, such as nasolabial folds.

Kinrix
Kinrix [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine] is a combination vaccine for protection against diphtheria, tetanus, pertussis and polio diseases in children.

Durezol
Durezol (difluprednate ophthalmic emulsion) is a topical steroid for the treatment of postoperative ocular inflammation and pain.

PrandiMet
PrandiMet (repaglinide and metformin HCl) is a fixed-dose combination of the fast-acting secretagogue replaglinide (also known as Prandin) and insulin sensitizer, metformin, indicated for the treatment of type 2 diabetes.

Pentacel
Pentacel is a combination vaccine indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive disease due to Haemophilus influenzae type b in children 6 weeks through 4 years of age.

Trivaris
Trivaris (triamcinolone acetonide) is a glucocorticoid corticosteroid delivered via intravitreal injection for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.

Entereg
Entereg (alvimopan) is a peripherally-acting mu opioid receptor antagonist used to help patients regain gastrointestinal (GI) function earlier following bowel resection surgery.

OraVerse
OraVerse is a dental anesthetic reversal agent that accelerates the return to normal sensation and function following dental procedures.

Aplenzin
Aplenzin is a once-daily formulation of bupropion hydrobromide indicated for the treatment of depression in adults.

Cimzia
Cimzia is a PEGylated anti-TNF (tumor necrosis factor) biologic therapy for the treatment of moderately to severely active Crohn’s disease in adults.

More...